| Description |
1 online resource : illustrations |
| Contents |
Front Cover; Treating Life-Threatening Bleedings; Copyright Page; Contents; About the Author; Preface and Acknowledgments; 1. Classical Bleeding Disease (Hemophilia); 1.1 The History of Hemophilia; 1.2 The Treatment of Hemophilia; 1.2.1 Fraction 1-0; 1.2.2 The clinical use of Fraction 1-0; 1.2.3 Prophylaxis in severe hemophilia; References; 2. My Encounter With Hemophilia (1959-82); 2.1 The Coagulation Laboratory in Malmö; 2.2 Hemophilia Patients With Inhibitors, and a Method to Stop Bleeding in These Patients; 2.3 Plasma FVIIa for Hemophilia Patients |
|
2.4 Treatment for the First Patients With FVIIa2.5 Potential Development of FVIIa to Be Used in Hemophilia; References; 3. The First Years at Novo Nordisk; 3.1 Recruitment by Novo Nordisk, 1983; 3.2 Hematology at Novo Industri During the 1980s; 3.2.1 The history of heparin and Novo Industri; 3.2.2 The development of modified heparins; 3.2.3 The development of LMWH at Novo Industri; 3.2.4 Substances to dissolve clots (thrombi); 3.2.5 The introduction of FVII at Novo Industri; References; 4. The Development of Recombinant FVIIa (rFVIIa) (1985-88); 4.1 Background and Start |
|
4.2 Work on Recombinant FVIIa4.2.1 The organization of the hemostasis group; 4.2.2 Production challenges; 4.2.3 The development of necessary assays; 4.2.4 Characterization of the rFVIIa molecule; 4.2.5 Effects and side effects: preclinical animal studies; 4.3 Treatment of the First Patient With rFVIIa, 1988; References; 5. The Further Use and Development of rFVIIa (1989-96); 5.1 The Prompt Use of rFVIIa; 5.2 rFVIIa as a "Compassionate Use" Product in the United States; 5.3 Plans for the Clinical Development of rFVIIa; 5.4 The Merger of Novo and Nordisk Gentofte 1989 and Its Consequences |
|
5.5 The Development and Licensing of rFVIIa 1990-965.6 The Development of Production Capacity and the US License; 5.7 Blood Product Advisory Committee, 1996; 5.8 Some Final Reflections; References; 6. Legal Issues Regarding the Use of rFVIIa in Hemophilia Patients With Inhibitors; 6.1 "Orphan Drug Act"; 6.2 Patent Rights (Intellectual Property); References; 7. Treatment With rFVIIa in Malmö (1996-99); 7.1 Part-Time Employment at the Coagulation Clinic in Malmö (1996-90); 7.2 The Third "Key Patient"; 7.3 What Did This Patient Teach Us?; References; 8. The Launching and Uses of rFVIIa |
|
8.1 The Launching of rFVIIa (1996-2000)8.2 rFVIIa for Use in Areas Other Than Hemophilia; 8.2.1 rFVIIa and platelet dysfunctions; 8.2.2 rFVIIa and liver diseases; 8.2.3 rFVIIa and patients with a normal coagulation system; 8.2.4 rFVIIa and trauma; 8.2.5 rFVIIa and patients with cerebral hemorrhages; References; 9. Mechanism of Action and Dosage; 9.1 Mechanism of Action; 9.2 Dosage; References; 10. The Continued Development of rFVIIa During the 2000s; 10.1 rFVIIa-Potential Long-term Effect; 10.1.1 The distribution in the blood of injected rFVIIa |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Online resource; title from PDF title page (EBSCO, viewed July 11, 2017) |
| Subject |
Blood coagulation factors.
|
|
Blood coagulation factor VIII.
|
|
Blood coagulation disorders -- Treatment
|
|
Hemophilia -- Treatment
|
|
1900s
|
|
2000s
|
|
Factor VIIa -- history
|
|
Blood Coagulation Disorders -- drug therapy
|
|
Recombinant Proteins -- therapeutic use
|
|
Blood Coagulation Factors
|
|
Factor VIII
|
|
HEALTH & FITNESS -- Diseases -- General.
|
|
MEDICAL -- Clinical Medicine.
|
|
MEDICAL -- Diseases.
|
|
MEDICAL -- Evidence-Based Medicine.
|
|
MEDICAL -- Internal Medicine.
|
|
Blood coagulation disorders -- Treatment
|
|
Blood coagulation factor VIII
|
|
Blood coagulation factors
|
|
Hemophilia -- Treatment
|
| Form |
Electronic book
|
| LC no. |
2017946970 |
| ISBN |
9780128124406 |
|
0128124407 |
|
